R&D News | pharmaphorum

News

AC Immune has announced positive interim results from its Ph 1 study of ACI-19764 – a NLRP3 inflammasome inhibitor targeting chronic inflammation.

News

Ultragenyx secured its first gene therapy approval, the FDA clearing GENGLYCOS as the first treatment designed to address underlying cause of GSDla.

News

Regeneron's Pasatru will be the second FDA-approved treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder.

News

Strong phase 3 results for Moderna's individualised skin cancer vaccine could pave the way for a leap forward in the field.

News

Network Bio launched today with $50 million in financing. It has also announced a collaboration with NVIDIA.

News

LEO Pharma is betting up to $435m on a pill that could give people with an ultra-rare light sensitivity disorder a way to spend more time outdoors.